ClinicalTrials.gg
Not yet recruitingNCT07266155Updated Dec 5, 2025

Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 2 interventional study of LP-005 Injection in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Longbio Pharma. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Planned enrollment
30th of 47
30 · median 40
Started
2025
with 11 others
Phase 2
13 of 51
4 open now
Primary completion
2027-12
later than 22 of 28 live
Registered
43rd of 51
by date
Lead sponsor
3 of 51
Longbio Pharma

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 30th largest by planned enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 22 of the 28 other live ones, and was the 43rd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

This is an extension study for patients who have completed a prior P10-LP005-02 clinical study. The aim of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of LP-005 injection in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients have fully understood the trial, have voluntarily agreed to participate in this clinical trial, and have signed a written Form (ICF).
  2. Patients who have completed the treatment of the Phase Ⅱ clinical study of LP-005 Injection and are assessed by the investigator as eligible for continued treatment with LP-005 Injection.
  3. Patients who have received Neisseria meningitidis vaccine and Streptococcus pneumoniae vaccine in accordance with the requirements of previous studies; if the vaccine protection period does not cover the treatment duration of this study, patients must agree to receive booster vaccination in a timely manner in accordance with the vaccine administration guidelines and the requirements of local vaccination institutions.
  4. Females and males of (including male subjects with female partners) must agree to use effective measures from the start of the trial until 3 months after the end of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have not completed the treatment of the Phase II clinical trial (P10-LP005-02) of the study drug.
  2. Patients who have completed the Phase II treatment phase but are unwilling to continue receiving the study drug treatment.
  3. Patients for whom the investigator does not recommend the continued use of LP-005 Injection after comprehensive assessment.
  4. Patients who did not participate in the Phase II clinical trial (P10-LP005-02) of the study drug.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    LP-005 1200 mg

    Patients will receive intravenous infusion of LP-005 Injection at a dose of 1200 mg once every 4 weeks.

    Biological: LP-005 Injection

  • Experimental
    LP-005 1500 mg

    Patients will receive intravenous infusion of LP-005 Injection at a dose of 1500 mg once every 4 weeks.

    Biological: LP-005 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Change from baseline in serum lactate dehydrogenase (LDH) levels.

    Time frame: Up to approximately 2 years

  2. Change from baseline in hemoglobin levels.

    Time frame: Up to approximately 2 years

  3. Proportion of patients who are transfusion-free.

    Time frame: Up to approximately 2 years

  4. Proportion of patients achieving hemoglobin levels ≥120 g/L

    Time frame: Up to approximately 2 years

  5. Proportion of patients with breakthrough hemolysis

    Time frame: Up to approximately 2 years

  6. Serum concentrations of LP-005.

    Time frame: Up to approximately 2 years

  7. Number of patients with anti-drug antibodies (ADA)

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2027, 24 months later.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 24 months is above that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 5, 2025
StartEst.
Dec 5, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
May 1, 2028
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07266155
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Dec 5, 2025 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Dec 5, 2025

Study contacts

Tingyuan Yang
Contact
yangty@longbiopharma.com
86-18611978535
Guangsheng He
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-005

Start the discussion